SITC 30th Anniversary Annual Meeting (2015): Mechanisms and Responses to Immune TherapyNovember 6-8, 2015 Gaylord National Hotel & Convention Center National Harbor, MDCo-Chairs:Thomas F. Gajewski, MD, PhD – University of ChicagoJennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer CenterSITC 30th Anniversary Annual Meeting Organizers Sandra Demaria, MD – Weill Cornell Medical College Madhav Dhodapkar, MD – Yale University Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre Jennifer A. Wargo, MD – University of Texas MD Anderson Cancer CenterAndrew D. Weinberg, PhD – Earle A. Chiles Research InstituteProgram SummaryMajor advances in cancer therapy have been made in the past several years through the use of immunotherapy, however limitations still exist. To address these limitations, there are ongoing efforts to better understand mechanisms of response and resistance to these forms of treatment. This session focused on these efforts, and highlighted contributions of both host and tumor-related factors to responses to immunotherapy. Topics covered included use of host genomic and immune data to predict and modulate responses to therapy, as well as host and tumor-specific contributions to responses in animal models as well as in longitudinal samples from patients on therapy. Specific insights into how to improve responses to therapy were also discussed.About the SITC 30th Anniversary Annual Meeting SITC's 30th Anniversary Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy research. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for both structured and informal discussions including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as ongoing SITC projects. Target AudienceThe target audience for this program included basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers that wished to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment. #Biomarkers #Melanoma #Video #AnnualMeeting #SITC #ImmuneCheckpointInhibitors #Ipilimumab #AlliedHealth #Clinician #Oncologist #Pharmacist #Researcher #2015
This library resource entry requires a SITC CONNECT account. Click the Sign In button at the top of this page, otherwise click here to create a FREE SITC CONNECT.
With a free SITC CONNET account, you can begin accessing hundreds of cancer immunotherapy resources in the SITC CONNECT Archive and Resource Libraries. Once your account is created, return to this page, refresh, and a download link should appear.
The SITC connectED education portal is supported by independent educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com